GlassScriptPhysician profile
Marco Martinez
NPI 1922542182
$5,161.89
in general payments reported to CMS, 2019-2025
33 companies · $893 in 2025
The $893 reported for 2025 was more than what 85% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $978 · 2022: $1,155 · 2023: $784 · 2024: $1,352 · 2025: $893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,029.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $693.75 | 2021-2024 | |
| Novo Nordisk INC | $693.31 | 2021-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $571.24 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $533.20 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $360.60 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.21 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $221.26 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $206.78 | 2021-2023 | |
| Amgen INC. | $200.34 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $179.26 | 2021-2024 | Watchman Flx, Watchman Access System, Watchman |
| Abbvie INC. | $143.58 | 2024-2025 | |
| Exact Sciences Corporation | $129.24 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $123.22 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $89.11 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.41 | 2023-2025 | Xifaxan, Trulance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $80.64 | 2021-2025 | Vest Therapy Und |
| Amarin Pharma, INC. | $58.86 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $53.96 | 2024-2025 | Zoryve |
| Abbott Laboratories | $51.55 | 2022-2023 | Freestyle Libre 3 |
| Biotronik INC. | $45.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.31 | 2022 | |
| Edwards Lifesciences Corporation | $37.19 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Idorsia Pharmaceuticals US INC | $33.87 | 2023 | Quviviq |
| Baxter Healthcare | $27.54 | 2023 | Hillrom - Life 2000 Ventilation System |
| Seqirus USA INC | $23.62 | 2025 | Flucelvax, Fluad |
| Otsuka America Pharmaceutical, INC. | $23.46 | 2025 | Jynarque |
| Teleflex LLC | $21.42 | 2024 | Urolift |
| Medtronic, INC. | $21.24 | 2022 | |
| Daiichi Sankyo INC. | $19.91 | 2021 | |
| Alnylam Pharmaceuticals INC. | $19.86 | 2023 | Amvuttra |
| Xeris Pharmaceuticals, INC. | $18.53 | 2025 | Keveyis |
| Si-Bone, INC. | $18.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marco Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.